| Helicobacter pylori is a bacterial pathogen existing in human stomach ,estimated to imfect half the world population, implicated in the etiology of peptic ulcer disease, chronic gastritis, gastric carcinoma and gastric mucosa-associated-lymphoid-tissure lymphoma. Although significiant progress has been made in treating this infection with combination of either triple antibiotics agents or triple antibiotics agents plus proton pump inhibitors, these antimicrobial-based treatment continue to be suboptimal. Immunization of at-risk individuals is the most cost- effective means of dealing with such a wide spread pathogen. Over the past few years, direct oral immunization inducing protcetion from infection at mucosal surface has been recognized. Using the Helicobacte felis or pylori mouse model, both prophylactic and therapeutic oral immunizations have been shown to be effective against Helicobacter pylori. Urease as the most potential candidate vaccines has been demonstrated effective and safety and a phase I clinical trial has been completed. Such antigens with combination with a safe mucosal adjuvant could be used as oral vaccine administrated to prevent and treat infection of Helicobacter pylori.
|
PDF Full Text Request